Navigation Links
Cervarix (Cervical Cancer) - Analysis and Forecasts to 2020
Date:10/18/2011

NEW YORK, Oct. 18, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Cervarix (Cervical Cancer) - Analysis and Forecasts to 2020

http://www.reportlinker.com/p0657234/Cervarix-Cervical-Cancer---Analysis-and-Forecasts-to-2020.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Cervarix (Cervical Cancer) - Analysis and Forecasts to 2020

Summary

GlobalData's pharmaceuticals report, "Cervarix (Cervical Cancer) - Analysis and Forecasts to 2020" provides Cervarix sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2007-2020). The report also includes information on Cervical Cancer market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Scope

- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)

- Analysis and review of Cervarix including sales data

- Qualitative and quantitative assessment of market space

- Analysis of the trends, drivers and restraints shaping and defining the markets

- In-depth analysis of Cervarix including efficacy, safety, pricing, competition and other details which influence its sales potential

- Detailed sales forecast for 2007-2020 for Cervarix in the seven major markets

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of competition by understanding the changing competitive landscape

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of the drug's performance

- Examine the historical sales performance of a drug in seven major markets

- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

1 Table of contents 3

1.1 List of Tables 4

1.2 List of Figures 4

2 Introduction 5

2.1 Cervical Cancer Vaccines Market 5

2.2 Epidemiology 5

2.3 Etiology 7

2.3.1 HPV Infections 7

2.3.2 Lack of Regular Papanicolaou (pap) Tests 8

2.3.3 Smoking 8

2.3.4 Sexual History 9

2.3.5 Birth Control Pills 9

2.4 GlobalData Report Guidance 9

3 Cervical Cancer Vaccines: Market Characterization 10

3.1 Cervical Cancer Vaccines Market 10

3.2 Drivers and Challenges for the Cervical Cancer Market 10

3.2.1 Drivers for Cervical Cancer Vaccine Market 10

3.2.2 Challenges for Cervical Cancer Vaccines 11

4 Cervarix 12

4.1 Introduction 12

4.2 Mechanism of Action 12

4.3 Clinical Studies 12

4.4 Approval History 13

4.5 Factors Affecting Sales of Cervarix 14

4.5.1 High Efficacy 14

4.5.2 High Cost Effectiveness 14

4.5.3 Large Target Population 14

4.5.4 Limited Competition 14

4.5.5 Low Compliance 14

4.6 Vaccine Evaluation 14

4.6.1 Efficacy 14

4.6.2 Safety 15

4.6.3 Dosing Convenience 15

4.7 Intensity of Competition 15

4.8 Sales forecast 15

4.8.1 Target Population of Cervarix 15

4.8.2 Dosing 16

4.8.3 Market Penetration 16

4.8.4 Annual Cost of Therapy 16

4.8.5 Sales Projections of Cervarix 16

5 Cervical Cancer Vaccine Market: Appendix 25

5.1 Market Definitions 25

5.2 List of Abberiviations 25

5.3 Research Methodology 25

5.3.1 Coverage 26

5.3.2 Secondary Research 26

5.3.3 Forecasting 26

5.3.4 Population Approved to take Vaccine 27

5.3.5 Net Penetration of Vaccine 27

5.3.6 Net Annual Dosing 27

5.3.7 Annual Cost of Therapy 27

5.3.8 Primary Research 27

5.3.9 Expert Panels 28

5.4 Contact Us 28

5.5 Disclaimer 28

5.6 Sources 28

1.1 List of Tables

Table 1: Cervical Cancer, Estimated Incidences and Mortality, 2010-2020 6

Table 2: Estimated Prevalence of HPV in 9-26 years women 8

Table 3: Cervarix History 13

Table 4: Cervarix Approval and Expiry 13

Table 5: Cervarix, Cervical Cancer, the US, EU-5 and Japan, Estimated Sales($m), 2007-2020 17

Table 6: Cervarix, Cervical Cancer, the US, Estimated Sales($m), 2009-2020 18

Table 7: Cervarix, Cervical Cancer, the UK, Estimated Sales($m), 2007-2020 19

Table 8: Cervarix, Cervical Cancer, France, Estimated Sales($m), 2007-2020 20

Table 9: Cervarix, Cervical Cancer, Germany, Estimated Sales($m), 2007-2020 21

Table 10: Cervarix, Cervical Cancer, Italy, Estimated Sales($m), 2007-2020 22

Table 11: Cervarix, Cervical Cancer, Spain, Estimated Sales($m), 2007-2020 23

Table 12: Cervarix, Cervical Cancer, Japan, Estimated Sales($m), 2009-2020 24

1.2 List of Figures

Figure 1: Estimated Prevalence of HPV in Women Aged between 9-26 Years in the US,EU-5 and Japan, 2010-2020 1

Figure 2: Cervarix, Cervical Cancer, the US, EU-5 and Japan, Estimated Sales($m), 2007-2020 2

Figure 3: Distribution of Incidence and Mortality, Global, Top 26 Diagnosed Cancers,2010 5

Figure 4: Difference Between Percentage Distribution of Incidence and Mortality of Top 19 Cancers, 2008 7

Figure 5: Per Capita Cigarette Consumption, the US, 1976-2006 8

Figure 6: Target Population 15

Figure 7: Cervarix, Cervical Cancer, the US, EU-5 and Japan, Estimated Sales($m), 2007-2020 17

Figure 8:Cervarix, Cervical Cancer, the US, Estimated Sales($m), 2009-2020 18

Figure 9:Cervarix , Cervical Cancer, the UK, Estimated Sales($m), 2007-2020 19

Figure 10:Cervarix, Cervical Cancer, France, Estimated Sales($m), 2007-2020 20

Figure 11:Cervarix, Cervical Cancer, Germany, Estimated Sales($m), 2007-2020 21

Figure 12:Cervarix, Cervical Cancer, Italy, Estimated Sales($m), 2007-2020 22

Figure 13:Cervarix, Cervical Cancer, Spain, Estimated Sales($m), 2007-2020 23

Figure 14: Cervarix, Cervical Cancer, Japan, Estimated Sales($m), 2009-2020 24

Figure 15: GlobalData Methodology 25

To order this report:

Pathology Industry: Cervarix (Cervical Cancer) - Analysis and Forecasts to 2020

Pathology Business News

More  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CDC Advisory Committee Recommends Cervarix To Prevent Cervical Cancer in Girls and Young Women
2. FDA Approves Cervarix, GlaxoSmithKlines Cervical Cancer Vaccine
3. GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval
4. CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date
5. GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection for More Than Six Years
6. Gardasil (Cervical Cancer) - Analysis and Forecasts to 2020
7. Saudi Arabia Medical Equipment Market Analysis and Forecasts to 2017
8. Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
9. Bare Metal Stents (BMS) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
10. Ophthalmic Diagnostic Equipment - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
11. Hip Resurfacing Implants - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
(Date:6/24/2016)... 2016  Consumers have taken a more active ... more emphasis on patient outcomes. ... the pharmaceutical industry have evolved beyond just providing ... are focusing on becoming more patient-oriented across their ... services that improve health. ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Comfort ... the American Cancer Society and the Road To Recovery® program to drive cancer patients ... seniors and other adults to ensure the highest quality of life and ongoing independence. ...
Breaking Medicine News(10 mins):